A Roche team has concluded that overreliance on simplistic, target-centered screens early in drug development may inadvertently select for compounds destined to fail in late-stage trials. The resulting high attrition rates and low R&D productivity could be reversed, the researchers believe, by refocusing discovery strategies on phenotypic screens that account for complex mechanisms of action and cell signaling pathways.